New class of Anti-inflammatory Drugs definedNon-steroid anti-rheumatic drugs (NSAR) such as acetylsalicylic acid (aspirin) have always been common and popular choices when it comes to treating pain, fever, and inflammation. But a recent study revealed that these drugs would not have passed even the clinical trial stage because of the risk factor and side-effects.

In order to find an effective alternative, a new approach has been developed using chemical substances belonging to the dual mPGES-1/5-LO-Inhibitors at the Manfred Schubert-Zsilavecz’s laboratory at the Goethe University.

According to Gerd Geisslinger, Speaker of the LiFF-Initiative and President of the Center for Drug Research, Development and Safety (ZAFES), this is one of the most important successes of their Lipid Signaling Research Centre.

The new class of drugs specifically targets the biosynthesis of prostaglandin and leukotrienes besides playing a pivotal role in inflammatory and allergic reactions.